INZY Insider Trading Activity and SEC Form 4 Filings
INZY insider trading summary
No open-market insider purchases or sales of Inozyme Pharma, Inc. (INZY) have been reported on SEC Form 4 in the past 12 months.
Latest INZY insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 2, 2025 | Douglas A Treco | CEO & Chairman | Sell | $8K (8,819 @ $0.89) |
| Apr 2, 2024 | Douglas A Treco | CEO | Sell | $52K (7,523 @ $6.94) |
| Aug 1, 2023 | Robert Lorne Hopfner | Insider | Buy | $3.4M (714,285 @ $4.80) |
| Aug 1, 2023 | Robert Lorne Hopfner | Insider | Buy | $571K (119,048 @ $4.80) |
| Aug 1, 2023 | Pivotal bioVenture Partners Fund I G.P., L.P. | Insider | Buy | $571K (119,048 @ $4.80) |
| Aug 1, 2023 | Pivotal bioVenture Partners Fund I, L.P. | Insider | Buy | $571K (119,048 @ $4.80) |
| Aug 1, 2023 | Pivotal bioVenture Partners Fund I G.P., L.P. | Insider | Buy | $3.4M (714,285 @ $4.80) |
| Aug 1, 2023 | Pivotal bioVenture Partners Fund I U.G.P. Ltd | Insider | Buy | $571K (119,048 @ $4.80) |
| Aug 1, 2023 | Pivotal bioVenture Partners Fund I, L.P. | Insider | Buy | $3.4M (714,285 @ $4.80) |
| Aug 1, 2023 | Pivotal bioVenture Partners Fund I U.G.P. Ltd | Insider | Buy | $3.4M (714,285 @ $4.80) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.